<DOC>
	<DOCNO>NCT00591214</DOCNO>
	<brief_summary>The purpose study assess safety , pharmacokinetics HCV ( Hepatitis C virus ) RNA ( Ribonucleic Acid ) kinetics administration MP-424 patient chronic hepatitis C .</brief_summary>
	<brief_title>Safety PK Study MP-424 Treat Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Patients diagnose genotype 1b chronic hepatitis C Patients naive concomitant medication interferon Patients diagnose decompensated cirrhosis Patients diagnose positive HBs ( Hepatitis B virus surface ) antigen test</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Protease Inhibitor</keyword>
</DOC>